Publications
Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.
Sponsored by Boehringer Ingelheim.
December 2025
A composite endpoint for systemic sclerosis–associated interstitial lung disease: association with mortality in two clinical trial cohorts
Respir Res. 2025;26(1):337 DOI : 10.1186/s12931-025-03401-8
Volkmann et al. validated a composite endpoint for systemic sclerosis–associated interstitial lung disease (SSc-ILD) using data from SLS II and compared performance with the SLS I cohort. The composite endpoint showed generalisability and demonstrated greater sensitivity for detecting treatment effects than forced vital capacity (FVC) alone.